Drug therapy is fundamental part of healthcare services. Increased cost of treatment is associated with the poor patient compliance and outcome. So, efforts should be made to choose the drug with minimum cost without affecting efficacy of the drugs. In tropical region like India, fungal infections are more common and some of them are life threatning. These superficial fungal infections require long term therapy significantly increasing the cost of therapy, so the treatment of fungal infection can raise economic burden on the patient. Cost in Indian Rupees (INR) of antifungal agents manufactured by different pharmaceutical companies in India was collected from the Current Index of Medical Specialities (CIMS), July – October 2018 issue. Minimum cost, Maximum cost, Cost ratio, Cost variation were calculated. Forty six percentage drugs show cost variation of more than 75%. In oral dosage form, Itraconazole, fluconazole and terbinafine show the maximum cost variation. In topical single drug therapy clotrimazole and miconazole show maximum cost variation. In topical combination therapy, combination of miconazole+ clobetasol+ gentamycin+ Zn sulphate shows maximum cost variation. There is wide cost variation among antifungal agents available in Indian Market. There is need of strict actions for cost policy regulation and sensitization of doctor for selection of appropriate brand drugs.